In a new job - March 11, 2019
Lundbeck appoints a new EVP and Chief Business Officer
The company has announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development from 4 April 2019. Keld will be part of Executive Management in his role as Executive Vice President, CBO. The new position is established as part of the revised strategy which […]
Collaboration - August 11, 2017
Lundbeck collaborates on study between genetics and psychiatric disorders
H. Lundbeck joins personal genetics company 23andMe and think tank the Milken Institute in a large new study to increase the understanding of the underlying causes of Major Depressive Disorder (MDD/unipolar depression) and Bipolar Depression. Further, the study will explore how these disorders and brain functions such as attention and decision-making are related to genetics. […]
Agreement - June 9, 2017
Lundbeck obtains rights to Alzheimer’s research
H. Lundbeck has entered into an agreement with biotech company ImmunoBrain Checkpoint for the rights to IBC’s groundbreaking research in the treatment of Alzheimer’s disease. The research focuses on modifying antibodies currently used in cancer treatment for use in treating the debilitating brain disease which 48 million patients are estimated to suffer from. A number […]
Clinical Trials - May 9, 2017
Lundbeck announces positive results from phase III trials
H. Lundbeck and Otsuka Pharmaceutical announce results from two phase III clinical trials evaluating the efficacy, safety and tolerability of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer’s type. The primary endpoint of both trials was change from baseline in the Cohen-Mansfield Agitation Inventory (CMAI) total score, a 29-item scale […]
Agreement - May 2, 2017
Lundbeck in conditional agreement and divests part of its headquarters
H. Lundbeck has signed a conditional agreement regarding the sale of properties (approximately 33,000 m2) on the Valby site in Copenhagen to the Danish pension funds Juristernes og Økonomernes Pensionskasse (JØP) and Danske civil- og akademiingeniørers Pensionskasse (DIP). Provided that the pre-specified conditions are met, Lundbeck will receive a cash payment of DKK 378 million […]
Drug Development Pharma - December 5, 2016
Lundbeck submitts New Drug Application to FDA
H Lundbeck and Otsuka Pharmaceutical Co have announced that the US Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for the expanded labeling of Abilify Maintena for the maintenance treatment of Bipolar I disorder in adult patients is sufficiently complete to permit a substantive review and is considered filed. […]
